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Introduction {#sec005}
============

The number of persons with dementia has been increasing rapidly worldwide in recent years, and has become a global issue associated with far-reaching medical and financial ramifications \[[@pone.0231226.ref001]--[@pone.0231226.ref005]\]. Although the increasingly elderly nature of the world's population provides the foundation for this trend, other factors include the promotion of government policies \[[@pone.0231226.ref002], [@pone.0231226.ref006], [@pone.0231226.ref007]\], increased clinical awareness \[[@pone.0231226.ref003]\], and drug treatment guidelines \[[@pone.0231226.ref008], [@pone.0231226.ref009]\].

At one time, psychiatric medications were commonly used as drug treatments for dementia \[[@pone.0231226.ref003], [@pone.0231226.ref010], [@pone.0231226.ref011]\]. However, in 1996, acetylcholinesterase inhibitors came on the market and began being used \[[@pone.0231226.ref012]\], and these were followed by NMDA receptor antagonists \[[@pone.0231226.ref013]\]. The use of these anti-dementia drugs subsequently increased rapidly \[[@pone.0231226.ref003], [@pone.0231226.ref014]\]. The English NICE guidelines initially limited the use of these drugs to severe cases of Alzheimer's dementia \[[@pone.0231226.ref015]\]. Some patients groups resisted these restrictions, and the drug company that developed donepezil and the distributors in the UK fought a protracted legal battle against the restrictions, eventually winning \[[@pone.0231226.ref016]--[@pone.0231226.ref018]\]. At present, there are no restrictions on the use of donepezil other than that its use be limited to patients with severe dementia. Acetylcholinesterase inhibitors and NMDA receptor antagonists are widely and routinely prescribed for the treatment of dementia by primary care physicians and other doctors who are not specialists in the treatment of dementia. In both Japan and the UK, donepezil has the leading market share of all of these drugs, followed by memantine and galantamine \[[@pone.0231226.ref019], [@pone.0231226.ref020]\].

Adverse events have been reported in patients using acetylcholinesterase inhibitor and NMDA receptor antagonist anti-dementia drugs. Typical adverse events that occur with the use of acetylcholinesterase inhibitors include gastrointestinal symptoms such as vomiting and diarrhea and psychiatric symptoms such as excitability, insomnia, and hallucinations \[[@pone.0231226.ref021]--[@pone.0231226.ref024]\]. Patients taking NMDA receptor antagonists sometimes experience adverse events such as dizziness and lightheadedness \[[@pone.0231226.ref023], [@pone.0231226.ref024]\].

Little research has been conducted analyzing adverse event data from patients taking anti-dementia drugs prescribed by physicians for patients with dementia in primary care settings. Specifically, little epidemiological research has been done where the researchers have obtained data on adverse events directly from the clinical setting and thereby gained an accurate understanding of the prevalence of and risk factors for adverse events \[[@pone.0231226.ref025]\]. One of the reasons for this is that physicians tend to underreport mild adverse events compared to serious adverse events \[[@pone.0231226.ref026], [@pone.0231226.ref027]\]. In addition, most of the anti-dementia drug epidemiology research that has been published has been conducted with funding from drug companies selling anti-dementia drugs, and show low rates for adverse event prevalence \[[@pone.0231226.ref028], [@pone.0231226.ref029]\]. Furthermore, although some information on the frequencies and risk factors for adverse events is available in electronic health records (EHR) \[[@pone.0231226.ref030]\], there are limits to the accuracy of this information because these are not databases that are intended primarily for the analysis of adverse events. The objective of this study was to clarify the types and frequencies of, and risk factors for, the adverse events that occur in patients taking anti-dementia drugs. We conducted a nationwide survey using a method for obtaining this information from the pharmacists who are handling these patients.

Methods {#sec006}
=======

1) Setting, study design and participants {#sec007}
-----------------------------------------

Setting: In the Japanese at-home care system, pharmacists working at community pharmacies visit patients at their homes and are responsible for obtaining patient consent and handling some of the drug treatment management work, following instructions received from physicians. Pharmacists who visit patients at home obtain patient data (on, for example, the drugs the patients have been prescribed and their disease, medical histories, and test results) as needed from the physicians who are handling the home care of these patients, and then when they visit the patients at their homes they collect information about the patients' symptoms, assess the efficacy of the drugs the patients are taking, collect information about the patient's treatment adherence, and collect information about any signs that could indicate that the patients have experienced drug-induced adverse events. They then determine whether or not this information has been reported to the doctors and if the doctors have been administering the drug therapies appropriately. However, there is not always close and smooth cooperation between the doctors and the pharmacists regarding the drug treatments that are administered in this home care system.

Study design: In this study, we had pharmacists who work for community pharmacies and were visiting patients at home fill out responses to a questionnaire. We conducted a nationwide survey using an original questionnaire on the drug therapies being taken by patients who are being visited at home by these pharmacists. We did not prepare a patient consent form because the data were collected anonymously. We asked these pharmacists to provide information on not more than 5 patients whom the pharmacists were visiting at home, whether or not they were taking anti-dementia drugs. The pharmacists were asked to fill out the questionnaire based on the most recent home visit services they had provided.

Questionnaires: The information about the patients that was obtained using the questionnaire included information about the patients' symptoms and treatment adherence, the appropriateness of the drug therapies, and signs that could indicate the presence of drug-induced adverse events. We conducted this survey by having the pharmacists who were the ones filling out the questionnaires answer questions that had been posted on a web page. The first step in our survey method was to reach out to pharmacists to inform them about the survey and enlist their participation. Specifically, we arranged for the inclusion in a journal that is published monthly by the Japan Pharmaceutical Association of the following insert: "Request for Participation in a Survey About Patient Drug Treatments Encountered in Pharmacists' Home Visit Activities, and Guide for Completing a Web-Based Questionnaire." As the second step, one managing pharmacist from each participating pharmacy (managing pharmacist at the pharmacy) was designated the person who would respond to the questionnaire, and these pharmacists were given access to a specific URL so that they could fill out the questionnaire. The questions were primarily multiple choice questions, although the pharmacists' opinions about their home visit duties were also collected using free response questions. The survey was conducted between January 10, 2018 and March 30, 2018.

2) Data collection {#sec008}
------------------

The data that we focused on collecting in this survey were data on the frequencies of adverse events, and the risk factors for developing these adverse events, that are experienced by patients who have been prescribed anti-dementia drugs. The survey items also included basic information about the patients (sex, age, level of nursing care required, primary disease, living situation) as well as the types of adverse events being experienced. In addition, in order to investigate the appropriateness of the drug therapies the patients were receiving, the survey also asked about patients' adherence to the treatments they were receiving when the pharmacists first visited them at home, as well as the numbers of drugs they were taking, and asked the pharmacists to assess the appropriateness of the use of anti-dementia drugs in these patients. In Japan, only 2 types of anti-dementia drugs are covered by health insurance, acetylcholinesterase inhibitors (donepezil, galantamine, and rivastigmine) and NMDA receptor antagonists (memantine), and this survey did not ask pharmacists for the names of the specific anti-dementia drugs their patients were taking.

3) Statistical analysis, approval of research ethics review, and role of the funding source {#sec009}
-------------------------------------------------------------------------------------------

In order to identify the factors associated with the adverse events being experienced by patients who have been prescribed anti-dementia drugs, univariate analyses were performed using a chi-squared test, a chi-squared test (for trend), or Fisher's exact test for the presence or absence of adverse events and for individual variables--that is, patient attributes (sex, age, level of nursing care, living situation), the number of drugs being by the patient when the pharmacist first visited the patient at home, the patient's treatment adherence when the pharmacist first visited the patient at home, and the pharmacist's assessment of anti-dementia drug efficacy. In addition, a multivariate logistic regression analysis was performed using as covariates those patient attributes having a P value of less than 0.20 in the univariate analyses. This study was reviewed and approved by the research ethics committee of the National Institute of Public Health of Japan. In addition, this study was funded by a research grant from the Ministry of Health, Labour and Welfare; no funding of any kind was received from any companies, groups, organizations, etc. with conflicts of interest.

Results {#sec010}
=======

Data on 3713 patients was received from 1673 pharmacies nationwide. There was no bias towards any particular region. After the data from patients for whom incomplete data had been collected (e.g., sex unknown, age unknown) were excluded, this left 3565 patients from whom data had been collected.

1) Basic patient attributes ([Table 1](#pone.0231226.t001){ref-type="table"}) {#sec011}
-----------------------------------------------------------------------------

The mean age of the patients was 80.1 years. There were 1411 male patients, accounting for 40% of the patient population, and 2154 female patients, accounting for 60% of the population. There were 2704 patients who were 75 years of age or older, and who therefore accounted for 79% of the population. The level of nursing care was II in 734 patients (22%) and I in 677 patients (20%). The most common primary disease was dementia, in 868 (26%) of the patients, followed by cardiovascular disease, in 607 (18%) of the patients, cerebral infarction in 410 (12%) of the patients, and cancer, in 276 (8%) of the patients. The most common living situation was living at home alone (1026, or 30%, of the patients), followed by living at home with family (844, or 24%, of the patients), and living in a communal home with caregiver support (806, or 23%, of the patients).

10.1371/journal.pone.0231226.t001

###### Attributes of patients being handled by the pharmacies surveyed (n = 3713).

![](pone.0231226.t001){#pone.0231226.t001g}

  Parameter                                 Category                                                                                
  ----------------------------------------- --------------------- -------- --------- -------- --------- -------- --------- -------- ---------
  Age                                       Mean                  77.6               81.3               80.1                        
  Age Distribution                          \< 75 years           399      (29.2)    341      (16.4)    740      (21.5)    763      (21.5)
  ≥ 75 and \< 80 years                      205                   (15.0)   263       (12.6)   468       (13.6)   476       (13.4)   
  ≥ 80 and \< 85 years                      294                   (21.5)   513       (24.7)   807       (23.4)   824       (23.2)   
  ≥ 85 and \< 90 years                      296                   (21.7)   491       (23.6)   787       (22.8)   812       (22.9)   
  ≥ 90                                      172                   (12.6)   472       (22.7)   644       (18.7)   676       (19.0)   
                                            Total                 1366     (100.0)   2080     (100.0)   3446     (100.0)   3551     (100.0)
  Nursing care level                        Independent           64       (4.8)     75       (3.7)     139      (4.1)     145      (4.2)
  Needed support grades Ⅰ-Ⅱ                 129                   (9.8)    220       (10.8)   349       (10.4)   356       (10.3)   
  Ⅰ                                         224                   (17.0)   453       (22.3)   677       (20.2)   700       (20.2)   
  Ⅱ                                         285                   (21.6)   449       (22.1)   734       (21.9)   757       (21.9)   
  Ⅲ                                         188                   (14.2)   286       (14.1)   474       (14.1)   486       (14.1)   
  Ⅳ                                         178                   (13.5)   225       (11.1)   403       (12.0)   425       (12.3)   
  Ⅴ                                         206                   (15.6)   273       (13.4)   479       (14.3)   492       (14.2)   
  Application pending                       13                    (1.0)    10        (0.5)    23        (0.7)    23        (0.7)    
  Unknown                                   34                    (2.6)    39        (1.9)    73        (2.2)    74        (2.1)    
                                            Total                 1321     (100.0)   2030     (100.0)   3351     (100.0)   3458     (100.0)
  Primary Disease                           Circulatory disease   226      (17.0)    381      (18.6)    607      (18.0)    641      (18.4)
  Cerebral infarction                       242                   (18.2)   168       (8.2)    410       (12.1)   421       (12.1)   
  Osteoarthritis                            24                    (1.8)    100       (4.9)    124       (3.7)    126       (3.6)    
  Fracture/osteoporosis                     22                    (1.7)    117       (5.7)    139       (4.1)    143       (4.1)    
  Rheumatoid arthritis                      9                     (0.7)    48        (2.3)    57        (1.7)    58        (1.7)    
  Amyotrophic lateral sclerosis             19                    (1.4)    23        (1.1)    42        (1.2)    46        (1.3)    
  Dementia                                  242                   (18.2)   626       (30.6)   868       (25.7)   891       (25.5)   
  Parkinson's disease                       64                    (4.8)    91        (4.4)    155       (4.6)    156       (4.5)    
  Other nerve disease                       54                    (4.1)    78        (3.8)    132       (3.9)    136       (3.9)    
  Chronic respiratory failure               88                    (6.6)    53        (2.6)    141       (4.2)    144       (4.1)    
  Cancer                                    147                   (11.0)   129       (6.3)    276       (8.2)    287       (8.2)    
  Renal failure                             28                    (2.1)    22        (1.1)    50        (1.5)    53        (1.5)    
  Other                                     167                   (12.5)   211       (10.3)   378       (11.2)   389       (11.1)   
                                            Total                 1332     (100.0)   2047     (100.0)   3379     (100.0)   3491     (100.0)
  Living Situation                          At home, alone        352      (25.6)    674      (32.2)    1026     (29.6)    1057     (29.5)
  At home, with spouse                      395                   (28.7)   269       (12.9)   664       (19.1)   673       (18.8)   
  At home, with family                      341                   (24.8)   503       (24.1)   844       (24.3)   878       (24.5)   
  At home, with someone other than family   15                    (1.1)    15        (0.7)    30        (0.9)    33        (0.9)    
  Communal living with assisted care        244                   (17.7)   562       (26.9)   806       (23.2)   842       (23.5)   
  Special nursing home                      30                    (2.2)    68        (3.3)    98        (2.8)    102       (2.8)    
                                            Total                 1377     (100.0)   2091     (100.0)   3468     (100.0)   3585     (100.0)

a: Including 148 subjects whose sex was unknown

2) Attributes of patients who were being prescribed anti-dementia drugs ([Table 2](#pone.0231226.t002){ref-type="table"}) {#sec012}
-------------------------------------------------------------------------------------------------------------------------

Of the patients who had been prescribed anti-dementia drugs, 264 (32%) were male and 573 (68%) were female. Patients who were 75 years old or older accounted for 764 (93%) of the patients who had been prescribed anti-dementia drugs, and patients with a level of nursing care of II accounted for 217 (27%) of these patients, and those with a level of nursing care of I accounted for 205 (26%) of these patients. The most common primary disease among patients prescribed anti-dementia drugs was dementia, in 539 (67%) of the patients, followed by cardiovascular disease, in 96 (12%), cerebral infarction, in 62 (8%), and Parkinson's disease, in 28 (4%). The most common living situation was living in a communal home with caregiver support, in 299 (37%) of the patients, living at home along, in 217 (27%) of the patients, and living at home with a spouse, in 148 (18%) of the patients.

10.1371/journal.pone.0231226.t002

###### Attributes of patients being prescribed anti-dementia drugs (n = 863).

![](pone.0231226.t002){#pone.0231226.t002g}

  Parameter                                 Category                                                                                
  ----------------------------------------- --------------------- -------- --------- -------- --------- -------- --------- -------- ---------
  Age                                       Mean                  23       (8.8)     38       (6.7)     61       (7.4)     62       (7.3)
  \< 75 years                               40                    (15.3)   81        (14.4)   121       (14.7)   123       (14.5)   
  ≥ 75 and \< 80 years                      75                    (28.7)   158       (28.0)   233       (28.2)   237       (27.9)   
  ≥ 80 and \< 85 years                      78                    (29.9)   169       (30.0)   247       (29.9)   253       (29.8)   
  ≥ 85 and \< 90 years                      45                    (17.2)   118       (20.9)   163       (19.8)   173       (20.4)   
                                            Total                 261      (100.0)   564      (100.0)   825      (100.0)   848      (100.0)
  Nursing care level                        Independent           2        (0.8)     3        (0.5)     5        (0.6)     5        (0.6)
  Assistance required levels Ⅰ-Ⅱ            16                    (6.2)    30        (5.4)    45        (5.6)    46        (5.5)    
  Ⅰ                                         53                    (20.5)   154       (27.6)   205       (25.6)   211       (25.2)   
  Ⅱ                                         70                    (27.1)   150       (26.9)   217       (27.1)   224       (26.8)   
  Ⅲ                                         49                    (19.0)   94        (16.9)   139       (17.4)   146       (17.4)   
  Ⅳ                                         31                    (12.0)   56        (10.1)   86        (10.7)   94        (11.2)   
  Ⅴ                                         30                    (11.6)   63        (11.3)   90        (11.2)   96        (11.5)   
  Application pending                       1                     (0.4)    2         (0.4)    3         (0.4)    3         (0.4)    
  Unknown                                   6                     (2.3)    5         (0.9)    11        (1.4)    12        (1.4)    
                                            Total                 258      (100.0)   557      (100.0)   801      (100.0)   837      (100.0)
  Primary Disease                           Circulatory disease   29       (11.2)    69       (12.1)    96       (11.9)    105      (12.3)
  Cerebral infarction                       34                    (13.1)   30        (5.3)    62        (7.7)    65        (7.6)    
  Osteoarthritis                            1                     (0.4)    11        (1.9)    12        (1.5)    12        (1.4)    
  Fracture/osteoporosis                     3                     (1.2)    8         (1.4)    11        (1.4)    13        (1.5)    
  Rheumatoid arthritis                      0                     (0.0)    7         (1.2)    6         (0.7)    7         (0.8)    
  Amyotrophic lateral sclerosis             1                     (0.4)    1         (0.2)    2         (0.2)    2         (0.2)    
  Dementia                                  153                   (58.8)   397       (69.9)   539       (66.5)   561       (65.9)   
  Parkinson's disease                       14                    (5.4)    15        (2.6)    28        (3.5)    29        (3.4)    
  Other nerve disease                       4                     (1.5)    9         (1.6)    13        (1.6)    13        (1.5)    
  Chronic respiratory failure               2                     (0.8)    3         (0.5)    4         (0.5)    5         (0.6)    
  Cancer                                    9                     (3.5)    8         (1.4)    17        (2.1)    17        (2.0)    
  Renal failure                             2                     (0.8)    3         (0.5)    5         (0.6)    5         (0.6)    
  Other                                     8                     (3.1)    7         (1.2)    15        (1.9)    17        (2.0)    
                                            Total                 260      (100.0)   568      (100.0)   810      (100.0)   851      (100.0)
  Living Situation                          At home, alone        57       (21.6)    164      (28.7)    217      (26.6)    225      (26.1)
  At home, with spouse                      81                    (30.7)   69        (12.1)   148       (18.2)   150       (17.4)   
  At home, with family                      40                    (15.2)   83        (14.5)   117       (14.4)   129       (15.0)   
  At home, with someone other than family   4                     (1.5)    3         (0.5)    5         (0.6)    7         (0.8)    
  Communal living with assisted care        77                    (29.2)   229       (40.0)   299       (36.7)   319       (37.0)   
  Special nursing home                      5                     (1.9)    24        (4.2)    29        (3.6)    31        (3.6)    
                                            Total                 264      (100.0)   572      (100.0)   815      (100.0)   861      (100.0)

a: Including 26 subjects whose sex was unknown

3) Presence or absence of adverse events, and disposition of adverse events ([Table 3](#pone.0231226.t003){ref-type="table"}) {#sec013}
-----------------------------------------------------------------------------------------------------------------------------

In the population of patients who had been prescribed anti-dementia drugs, adverse events were confirmed in 43 (17%) of the males and 122 (23%) of the females, and thus in 170 (21%) of the population prescribed anti-dementia drugs overall. The disposition of adverse events was as follows: excitement/insomnia, in 74 (45%) of patients; nausea/vomiting/diarrhea, in 55 (34%) of patients; hallucinations/delusions/visual hallucinations, in 35 (21%) of patients; and poriomania/violent behavior, n 26 (16%).

10.1371/journal.pone.0231226.t003

###### Disposition of confirmed adverse events in patients prescribed anti-dementia drugs (n = 863) (Multiple answers possible).

![](pone.0231226.t003){#pone.0231226.t003g}

                                                Male   Female   Overall                                                      
  --------------------------------------------- ------ -------- --------- ------ ------------------------------------------- ------
  Overall                                       43              122              170[^b^](#t003fn002){ref-type="table-fn"}   
  Excitement/insomnia                           23     57.5     48        40.3   74                                          45.1
  Nausea/vomiting/diarrhea                      12     30.0     43        36.1   55                                          33.5
  Hallucination/delusion/visual hallucination   14     35.0     20        16.8   35                                          21.3
  Poriomania/violent behavior                   6      15.0     18        15.1   26                                          15.9
  Patch-induced rash                            6      15.0     10        8.4    17                                          10.4
  Parkinson's-like symptoms                     6      15.0     8         6.7    14                                          8.5
  Pollakiuria/incontinence                      7      17.5     5         4.2    12                                          7.3
  Dizziness                                     0      0.0      8         6.7    8                                           4.9
  Bradycardia/arrhythmia                        3      7.5      2         1.7    5                                           3.0
  Other                                         2      5.0      5         4.2    7                                           4.3

a: Excluding subjects from whom responses were not obtained

b: Including 5 subjects whose sex was unknown

4) Factors associated with the emergence of adverse events ([Table 4](#pone.0231226.t004){ref-type="table"}) {#sec014}
------------------------------------------------------------------------------------------------------------

[Table 4](#pone.0231226.t004){ref-type="table"} shows the results of a statistical analysis that was performed in order to investigate factors associated with the adverse events identified by the pharmacists. The overall rate of adverse events was 20.9%. Sex, level of nursing care, the number of drugs being taken when the pharmacist first visited the patient at home, the patient's adherence with anti-dementia drug treatment, and the pharmacist's assessment of the applicability of prescribing anti-dementia drugs were identified as marked factors contributing to the development of adverse events. The odds ratio, adjusted for sex and level of nursing care, was 1.51 (95% CI: 1.04--2.19) for a number of drugs when the pharmacist first visited the patient at home of 10 or more, 1.55 (95% CI: 1.03--2.31) for an anti-dementia drug treatment adherence of "forgets to take medication 1--2 times a week," and 2.85 (95% CI: 1.46--5.60) for an assessed applicability of the prescription of an anti-dementia drug of "inappropriate." A high number of drugs being taken when the pharmacist first started visiting the patient at home, an anti-dementia drug treatment adherence of "forgets to take medication 1--2 times a week," and the inappropriate use of an anti-dementia drug prescription were identified as three statistically significant risk factors.

10.1371/journal.pone.0231226.t004

###### Factors associated with adverse event emergence.

![](pone.0231226.t004){#pone.0231226.t004g}

  Factor                                                           N                    \%                                                          Adverse Event Emergence   p-value   OR[a](#t004fn001){ref-type="table-fn"}        95%CI                                         p-value                                                             
  ---------------------------------------------------------------- -------------------- ----------------------------------------------------------- ------------------------- --------- --------------------------------------------- --------------------------------------------- --------------------------------------------- ------ -------------- -------
  Overall [^b^](#t004fn002){ref-type="table-fn"}                   812                  100.0                                                       170                       20.9                                                                                                                                                                      
  Patient Characteristic                                                                                                                                                                                                                                                                                                                                
                                                                   Sex                                                                                                                                                                0.090[^c^](#t004fn003){ref-type="table-fn"}                                                                       
                                                                                        Male                                                        248                       31.5      43                                            17.3                                                                                                              
                                                                                        Female                                                      539                       68.5      122                                           22.6                                                                                                              
                                                                   Age                                                                                                                                                                0.244[^d^](#t004fn004){ref-type="table-fn"}                                                                       
                                                                                        Mean                                                        58                        7.2       10                                            17.2                                                                                                              
                                                                                        \< 75 years                                                 117                       14.6      24                                            20.5                                                                                                              
                                                                                        ≥ 75 and \< 80 years                                        227                       28.3      44                                            19.4                                                                                                              
                                                                                        ≥ 80 and \< 85 years                                        235                       29.3      51                                            21.7                                                                                                              
                                                                                        ≥ 85 and \< 90 years                                        164                       20.5      39                                            23.8                                                                                                              
                                                                   Nursing care level                                                                                                                                                 0.052[^c^](#t004fn003){ref-type="table-fn"}                                                                       
                                                                                        Independent/Assistance Required/Nursing Care Levels I-II    454                       58.7      87                                            19.2                                                                                                              
                                                                                        Ⅲ - Ⅴ                                                       320                       41.3      80                                            25.0                                                                                                              
                                                                   Living Situation                                                                                                                                                   0.395[^c^](#t004fn003){ref-type="table-fn"}                                                                       
                                                                                        At home, alone                                              206                       25.4      38                                            18.4                                                                                                              
                                                                                        At home, with spouse                                        139                       17.1      26                                            18.7                                                                                                              
                                                                                        Home, living with someone else                              129                       15.9      33                                            25.6                                                                                                              
                                                                                        Communal living with assisted care / Special nursing home   337                       41.6      73                                            21.7                                                                                                              
  Number of drugs being taken at the first pharmacist home visit                                                                                                                        0.019[^c^](#t004fn003){ref-type="table-fn"}                                                                                                                     
                                                                                        0 -- 9                                                      530                       69.6      100                                           18.9                                                                                        ref                   
                                                                                        10 -                                                        231                       30.4      61                                            26.4                                                                                        1.51   (1.04, 2.19)   0.030
  Treatment adherence at first pharmacist home visit                                                                                                                                    0.064[^c^](#t004fn003){ref-type="table-fn"}                                                                                                                     
                                                                                        Not adherent/only taking medication 1--2 times a week       167                       21.2      27                                            16.2                                          0.562[^d^](#t004fn004){ref-type="table-fn"}   0.91   (0.55, 1.51)   0.717
                                                                                        Forgets to take medication 1--2 times a week                230                       29.2      59                                            25.7                                                                                        1.55   (1.03, 2.31)   0.034
                                                                                        Takes medication as directed                                390                       49.6      79                                            20.3                                                                                        ref                   
  Appropriateness of anti-dementia drug therapy                                                                                                                                         0.009[^e^](#t004fn005){ref-type="table-fn"}                                                                                                                     
                                                                                        Determined to be not appropriate                            42                        5.3       16                                            38.1                                                                                        2.85   (1.46, 5.60)   0.002
                                                                                        Determined to be appropriate                                753                       94.7      147                                           19.5                                                                                        ref                   

a: adjusted for sex and level of nursing care

b: Including subjects from whom responses were not obtained for each factor

c: Chi-square test

d: p for trend

e: Fisher\'s exact test

Discussion {#sec015}
==========

This nationwide survey found that the prevalence of adverse events that were determined by the attending pharmacists to have been caused by anti-dementia drugs in patients receiving anti-dementia drugs exceeded 20%. Although anti-dementia drugs have been widely adopted since they came onto the market, and are now a commonly encountered drug therapy, little research has been done to enable an accurate understanding of the prevalence of adverse events occurring in patients receiving such therapy. The reports that have been published to date include reports of the results of postmarketing surveillance \[[@pone.0231226.ref028], [@pone.0231226.ref029]\], a report based on HER data \[[@pone.0231226.ref030]\], and a report from a relatively small-scale observational study \[[@pone.0231226.ref031]\]. These were all studies that were funded by drug companies, and it is possible that they underestimate the adverse events that occurred because of, for example, reporting bias. Our study, however, was conducted using public research funds, and the data were collected using a unique methodology that makes it possible for pharmacists, who are drug product specialists, to evaluate whether or not adverse events occurred. Our study found a higher incidence of adverse events than the studies that have been conducted to date. Our results suggest that adverse events resulting from anti-dementia drug therapy are more common than has been acknowledged to date.

The most common adverse event in both males and females was excitement/insomnia, occurring in close to half (45.1%) of patients. Poriomania/violent behavior occurred in 21.3%. It was clear, in other words, that excessive mental excitement and uncontrollable physical movement is a frequent and marked adverse event in anti-dementia drug therapy. There is a previous report stating that excitement/insomnia associated with adverse events in anti-dementia drug therapy suggests that the dose being taken is not appropriate \[[@pone.0231226.ref032]\]. Because acetylcholinesterase inhibitors are metabolized by the liver and NMDA receptor antagonists are excreted renally, in elderly patients in whom these functions are reduced, it is likely that the blood concentrations that are optimal for therapy could be exceeded, resulting in mental excitement. The patients who were studied in our research had an average age of more than 80 years, and had reduced hepatic and renal functions \[[@pone.0231226.ref033]\]. It is possible that these patients' attending physicians imprudently prescribed anti-dementia drugs without regularly assessing the patients' renal and hepatic function, leading to the patients having excessively high blood levels of the drugs, and thus in the frequent emergence of adverse events.

Although there was no significant difference between the sexes in the incidence of adverse events (P = 0.090), they were more common in female patients. Although there are few reports on differences between the sexes in the incidence of adverse events \[[@pone.0231226.ref034]\], it is known that females generally experience more adverse events in drug therapy \[[@pone.0231226.ref035]\]. This is attributed to the fact that women more often take doses that are too high, and to the pharmacokinetics and/or pharmacodynamics. However, it was thought that the reason that the incidence of adverse events was higher in females in this study was that in the distribution by age, although the difference was not significant (P = 0.153), there were more elderly patients among the females (of the 410 patients who were 85 years old or older, 47.1% were male and 50.9% were female).

The nursing care levels described in this study (I through V) were assigned primarily depending on the patient's level of physical ability (freedom in performing activities of daily living), with a level of nursing care of III or above indicating that the patient has difficulty in performing activities of daily living. Patients with a greater need for nursing care were more likely to experience adverse events than patients without such a need (P = 0.052). Such patients may have developed more adverse events because their drug metabolizing functions are generally weakened. Caution should be exercised when using anti-dementia drugs in patients requiring a high level of nursing care.

The mean number of drugs being prescribed to the patients who had been prescribed anti-dementia drugs and had experienced adverse events (n = 170) was 8 (SD = 4.33). It was found that patients who had been taking 10 or more types of drugs per day when first visited at home by the pharmacists, before any pharmacist interventions (231 patients, of whom 61 had developed adverse events) had a significantly higher (P = 0.019) incidence of adverse events than patients who had been taking 9 or fewer types of drugs per day (530 patients, of whom 100 had developed adverse events). The patients' attending physicians were not exclusively dementia specialists, they also included primary care physicians, circulatory medicine specialists, and gastroenterologists. There were patients who had also been prescribed various medications by physicians in multiple specialties, including orthopedic surgery and neurology, and information about the drugs that an individual patient was being prescribed was not necessarily being shared among all of the patient's doctors. It was confirmed that the prescribing of multiple drugs to patients receiving anti-dementia drugs made it more likely that these patients would develop adverse events, and this finding is consistent with the results of a study that was conducted previously in patients hospitalized at a single site \[[@pone.0231226.ref025]\].

Looking at patient treatment adherence when the patients were first visited at home by the pharmacists, it was found that patients who "forgot to take their medication 1--2 times a week" experienced significantly (P = 0.034) more adverse events than either patients who took their medication as directed or patients who hardly took their medication at all. This could be because when a patient resumes taking medication after the blood level of the drug has fallen because of a break in the treatment, the blood level either suddenly increases, or else the extent of the increase is greater than it would normally be, making it more likely that the patient will experience nausea or vomiting, or excitement or insomnia \[[@pone.0231226.ref032]\].

We asked the pharmacists to assess whether or not anti-dementia drugs were being used in patients for whom they are appropriate. The responses showed that in the 42 patients for whom the pharmacists determined that the use of anti-dementia drugs was inappropriate, 38.1% of the patients experienced adverse events, compared to an incidence of 19.5% in the group of 753 patients for whom the pharmacists determined that the use of anti-dementia drugs was appropriate (P = 0.009). In Japan, there are few options for the treatment of dementia other than drug therapy, and the treatment guidelines strongly recommend the use of anti-dementia drugs. This has resulted in anti-dementia dugs being used inappropriately in patients including elderly patients 85 years of age or older for whom there is little evidence to support the use of such therapy \[[@pone.0231226.ref036]\]. In the UK, the efficacy and applicability of the use of anti-dementia drugs has been contentious for a long time \[[@pone.0231226.ref016]--[@pone.0231226.ref018]\]. The National Institute for Health and Care Excellence (NICE) recommends that a patient's cognitive function, physical function, and functional/behavioral symptoms be assessed and reviewed regularly, and that therapy be continued only if the therapy is being found to afford efficacy \[[@pone.0231226.ref008]\]. This has helped to prevent the misuse of anti-dementia drugs and to promote the appropriate use of drug therapy.

This study had several limitations regarding participant recruitment and the assessments of the adverse events the patients were experiencing and the appropriateness of the drugs the patients were being prescribed. The first was that there may have been some bias in participant recruitment and data collection. Participant recruitment involved, as the first step, soliciting participation in the study from all of the members of the Japan Pharmaceutical Association by enclosing an invitation form in an issue of the Journal of the Japan Pharmaceutical Association. The pharmacists who participated in this study therefore likely constitute a pharmacist subpopulation that has a relatively high level of clinical expertise and a relatively high level of interest in anti-dementia drugs, and this means that some selection bias may be present. In addition, this study was not a typical retrospective survey; participants received the following instructions: "Please respond to the following questions about the patients to whom you are currently providing home visitation services. Please provide information on up to 5 such patients, regardless of whether or not they are taking anti-dementia drugs." In other words, the questions focused on collecting information about the current symptoms, prescriptions, treatment adherence, etc. of the patients. Pharmacists were not asked for information about, for example, events that occurred in the past or about patients' previous illnesses. Therefore, we think that there is virtually no recollection bias in the responses that were received. Secondly, as far as the pharmacists' understanding of the adverse events is concerned, although the responding pharmacists were not pharmacists who specialize in anti-dementia drug therapy, because the adverse events that occurred are not events that require a high degree of specialization to diagnose, we think that on the whole the current understanding of the patients' adverse events is accurate. However, we are not able to conclusively rule out the potential involvement in these adverse events of anti-dementia drugs or other factors (e.g., existing psychiatric or gastrointestinal illness, Meniere's disease, other lifestyle or stress factors). Thirdly, the questionnaire defined "inappropriate anti-dementia drug use" as cases in which either "the physician continued to prescribe an anti-dementia drug even though the patient had severe dementia for which the anti-dementia drug was not indicated" or "the physician continued to prescribe an anti-dementia drug despite the fact that the therapeutic efficacy of the drug was not being regularly assessed and clear efficacy was not being achieved." The pharmacists responded to the survey questions based on these definitions. In Japan, most pharmacist home visitation services are provided based on the instructions of a primary care physician, and may include the prescribing of anti-dementia drugs. Japanese pharmacist home visitation services also include cases where both the physician and the pharmacist visit the patient together. It should be noted that, in Japan, neurologists specializing in dementia work full-time at their offices, and do not make home visits. Because there are no standardized assessment tools or criteria that are used by pharmacists to allow for a more rigorous assessment of "inappropriate anti-dementia drug use," such assessments vary depending on factors including the pharmacist's ability and experience, and there consequently may have been some limitations in terms of the accuracy and consistency of these assessments.

The objective of this study was not to gain an understanding of what kinds of adverse events are caused by specific anti-dementia drugs or drug interactions. This study was conducted using a method that was different from conventional approaches in that it used data obtained directly from pharmacists, instead of, for example, the analysis of data from existing EHRs or physician reports. The use of anti-dementia drugs took off as soon as they became commercially available. They are now prescribed too readily, assessment of their efficacy is often perfunctory, and adverse events are often overlooked. We investigated the prevalence of and risk factors for adverse events caused by anti-dementia drugs using a unique method, although this method may have some limitations. We hope the findings from our study will help improve the safety and efficacy of anti-dementia drugs in patients for whom they are prescribed.

10.1371/journal.pone.0231226.r001
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Reviewer \#1: This study aims to identify types, prevalence, and risk factors of adverse events for patients receiving anti-dementia drugs in Japan.

A national wide survey was used to collect the information from pharmacists. The author found that 1) the most common type of adverse event is excitation/anxiety; 2) 21% of prevalence; 3) polypharmacy, inappropriate use, and irregular medication use are identified as potential risk factors for the adverse events.

This is an interesting study. The main limitation about this study is data collection and data harmonization. And the author acknowledges this limitation in this discussion part.

My main questions are:

1\) How many dementia patients pharmacists typically deal with in this survey? Because this survey is retrospective, the accuracy about this questionnaire completely depends on the pharmacists' memory and experience.

2\) Are those pharmacists specialized in dementia symptoms only?

3\) Can you also differentiate the two columns of p value in Table 4?

Reviewer \#2: The study presented by the Authors is a survey based on pharmacists\' responses to a questionnaire on anti-dementia drugs.

The only quantitative data the Authors found were that: 1) 21% of patients taking anti-dementia drugs showed adverse events of any kind; 2) the most relevant factors in predicting adverse events were: taking more than 10 drugs contemporarily and inappropriate use of anti-dementia drugs (as judged by the pharmacists).
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3\) quantitative analyses (i.e. those requiring statistical procedures) were only a minimal part of the manuscript, while the great part of it reported descriptive data, which are of limited scientific interest

4\) no consideration was given to the possibility that multiple mediator factors may explain the association between exposure to anti-dementia drugs and adverse events.

4a) Taking 9-10 concurrent drugs with anti-dementia drugs was one significant risk factor of adverse events. How can it be excluded that the adverse events were caused by one of the 9-10 concurrent drugs or (even more plausible) by the pharmacodynamics/pharmacokinetics of these associations?

4b) What does it mean \"inappropriate use\" of anti-dementia drugs? How can pharmacists have all the information to judge upon the appropriateness of anti-dementia agents\' prescription? Were the anti-dementia agents prescribed by primary-care physicians or by dementia specialists?
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Reviewer \#1: This study aims to identify types, prevalence, and risk factors of adverse events for patients receiving anti-dementia drugs in Japan.

A national wide survey was used to collect the information from pharmacists. The author found that 1) the most common type of adverse event is excitation/anxiety; 2) 21% of prevalence; 3) polypharmacy, inappropriate use, and irregular medication use are identified as potential risk factors for the adverse events.

This is an interesting study. The main limitation about this study is data collection and data harmonization. And the author acknowledges this limitation in this discussion part.

My main questions are:

1\) How many dementia patients pharmacists typically deal with in this survey? Because this survey is retrospective, the accuracy about this questionnaire completely depends on the pharmacists' memory and experience.

2\) Are those pharmacists specialized in dementia symptoms only?

3\) Can you also differentiate the two columns of p value in Table 4?

Response to Reviewer\#1:

We are grateful for your careful review of our manuscript. Below, we will respond to your questions about our manuscript, and provide a supplemental explanation of the procedures that were used for data collection, harmonization, etc.

The method used to recruit respondents for this study was largely the same as the method that was used in a preceding study for which I, the lead author of this paper, was the principal investigator (BMJ Open. 2015 Aug 10;5(8):e007581. doi: 10.1136/bmjopen-2015-007581. PMID: 26260347. Correspondence to Hirohisa Imai); the only difference was the use of a paper questionnaire versus the use of a web-based questionnaire. Please refer to this aforementioned report.

Respondents were recruited in 2 stages. In the first stage, with the cooperation of the Japan Pharmaceutical Association, an invitation form soliciting participants for this study was enclosed in an issue of the Journal of the Japan Pharmaceutical Association, which is sent to all of the association's members. In the second stage, the managing pharmacist of the pharmacy (the pharmacy manager) was designated as the person who would complete the questionnaire, and this pharmacy manager then accessed our web site and responded to the question items. We asked the responding pharmacists to enter into the questionnaire the information for up to 5 patients to whom the pharmacists had been providing home visitation services, regardless of whether or not the patients had been receiving anti-dementia drugs. The pharmacists were asked to enter information about the home visitation services that they personally had been providing.

Furthermore, we would like to point out that we set "up to 5" as the number of patients for whom information should be reported on the basis of the recruitment results of a pilot survey that had been conducted prior to this nationwide survey. Another reason was to reduce the burden placed on the pharmacists and thereby ensure a better response rate, and also to eliminate the effects of marked variations among the pharmacies in the number of patients.

1\) How many dementia patients pharmacists typically deal with in this survey? Because this survey is retrospective, the accuracy about this questionnaire completely depends on the pharmacists' memory and experience.

Response:

1\) Of the patients whose cases were being handled by each pharmacist and out of whom up to 5 were selected at the pharmacist's discretion, on average, 0.76 out of 5 patients were taking anti-dementia drugs. Although there were some pharmacists who only submitted information on 1 patient, out of all of the patients for whom information was submitted by 1136 pharmacists, there were 863 patients who were taking anti-dementia drugs, and the aforementioned average figure of 0.76 was calculated by dividing the number of patients taking anti-dementia drugs (863) by the total number of reporting pharmacists (1136).

The responding pharmacists were given the following instructions regarding this questionnaire: "Please respond to the following questions about the patients to whom you are currently providing home visitation services"; and "Please provide information on up to 5 such patients, regardless of whether or not they are taking anti-dementia drugs." This study was therefore not a typical retrospective study, as we focused on questions about the "current" symptoms, medications, treatment adherence status, etc. of the patients. We did not ask for information about past illnesses or treatments. We therefore think that there is virtually no recollection bias in the responses that were received.

2\) Are those pharmacists specialized in dementia symptoms only?

Response:

2\) The responding pharmacists were not pharmacists who specialize in anti-dementia drug therapy. Therefore, the correctness of the decisions about the causal relationships between an adverse event had and an anti-dementia drug or about whether or not an anti-dementia drug was being used appropriately may, as was pointed out by Reviewer \#1, vary somewhat depending on the pharmacist's ability and experience. As is explained in our manuscript, because the pharmacists did not, for example, use any assessment tools, I think that the levels of objectivity and accuracy were not as high as they could have been. Although we stated in the manuscript that "because these adverse events were not symptoms that would require a great deal of expertise to diagnosis . . . we concluded that the patients' adverse events had generally been assessed accurately," we have rewritten this sentence to read as follows: ". . . because these adverse events were not events that require a high degree of specialization to diagnose, we think that on the whole the current understanding of the patients' adverse events is accurate. However, we are not able to conclusively rule out the potential involvement in these adverse events of anti-dementia drugs or other factors (e.g., existing psychiatric or gastrointestinal illness, Meniere's disease. or other lifestyle or stress factors).

3\) We understand your request to explain the difference in the P values on the left and right of Table 4. The P values on the right are the values for a multivariate analysis; we have noted this by putting a superscript "a" next to "P value" at the top of the right-hand column.

Reviewer \#2: The study presented by the Authors is a survey based on pharmacists\' responses to a questionnaire on anti-dementia drugs.

The only quantitative data the Authors found were that: 1) 21% of patients taking anti-dementia drugs showed adverse events of any kind; 2) the most relevant factors in predicting adverse events were: taking more than 10 drugs contemporarily and inappropriate use of anti-dementia drugs (as judged by the pharmacists).

These data appear too poor to grant their publication in Plos One and should better suit on a journal with less impact factor, eg a regional journal, also given their local resonance.

Most of all, these data were compromised by multiple methodological flaws:

Response to Reviewer\#2:

We appreciate your review, although it was critical of our manuscript. It appears to us that you found our initially submitted manuscript insufficiently convincing because our explanations were inadequate and/or lacking in clarity. We would like to provide a more complete explanation showing that our research yielded findings that can help to solve the problems that are associated with anti-dementia drugs and is therefore worthy of being published in PLOS One.

The method used to recruit respondents for this study was generally the same as the method that was used in a preceding study for which I, the lead author of this paper, was the principal investigator (BMJ Open. 2015 Aug 10;5(8):e007581. doi: 10.1136/bmjopen-2015-007581. PMID: 26260347. Correspondence to Hirohisa Imai); the only difference was the use of a paper questionnaire versus the use of a web-based questionnaire. Please refer to this aforementioned report.

Respondents were recruited in 2 stages. In the first stage, with the cooperation of the Japan Pharmaceutical Association, an invitation form soliciting participants for this study was enclosed in an issue of the Journal of the Japan Pharmaceutical Association, which is sent to all of the association's members. In the second stage, the managing pharmacist (pharmacy manager) of the pharmacy was designated as the person who would complete the questionnaire, and this pharmacy manager then accessed our web site and responded to the question items. We asked the responding pharmacists to enter into the questionnaire the information for up to 5 patients to whom the pharmacists had been providing home visitation services, regardless of whether or not the patients had been receiving anti-dementia drugs. The pharmacists were asked to enter into the questionnaire information about the home visitation services that they personally had been providing.

Furthermore, we would like to point out that we set "up to 5" as the number of patients for whom information should be reported on the basis of the recruitment results of a pilot survey that had been conducted prior to this nationwide survey. Another reason was to reduce the burden placed on the pharmacists and thereby ensure a better response rate, and also to eliminate the effects of marked variations among the pharmacies in the number of patients.

1\) the main goal of the study was not clearly stated. Authors should specify the aim of the study and should also indicate the outcome measure they wanted to examine (eg. rate of adverse events)

Response:

We have revised the description of the study's objectives to read as follows:

"The objective of this study is to clarify the types and frequencies of, and risk factors for, the adverse events that occur in patients taking anti-dementia drugs."

We have also added the following sentence to the "Results" section: "The overall rate of adverse events was 20.9%."

2\) recruitment of respondents and data collection exposed to the risk of multiple biases, mostly selection and recalling bias, and the Authors did not mention how they managed them. Neither they discussed these possible biases in the Limitation section

Response:

This study was not a typical retrospective survey; participants received the following instructions: "Please respond to the following questions about the patients to whom you are currently providing home visitation services. Please provide information on up to 5 such patients, regardless of whether or not they are taking anti-dementia drugs." In other words, the questions focused on collecting information about the current symptoms, prescriptions, treatment adherence, etc. of the patients. Pharmacists were not asked for information about, for example, events that occurred in the past or about patients' previous illnesses. Therefore, we think that there is virtually no recollection bias in the responses that were received. Regarding selection bias, the pharmacists who participated in this study likely constitute a pharmacist subpopulation that has a relatively high level of interest in anti-dementia drugs. We did not implement any measures for avoiding this selection bias when we recruited study participants or performed the data analysis. Some selection bias may therefore be present.

We have revised our description of the limitations in the "Discussion" section to read as follows: "We solicited participation in this study from all of the members of the Japan Pharmaceutical Association through an invitation form that was enclosed in an issue of the Journal of the Japan Pharmaceutical Association. The pharmacists who participated in this study likely constitute a pharmacist subpopulation that has a relatively high level of clinical expertise and a relatively high level of interest in anti-dementia drugs. Some selection bias may therefore be present."

3\) quantitative analyses (i.e. those requiring statistical procedures) were only a minimal part of the manuscript, while the great part of it reported descriptive data, which are of limited scientific interest

Response:

Aside from performing the multivariate logistic regression analysis presented in Table 4, we did not apply any other higher-order statistical procedures. However, we think that we have appropriately described the fundamental data, and that the chi-squared, Fisher's exact, and trend tests have been appropriately utilized and are appropriate given the nature of the data. These basic statistical procedures required few assumptions compared to higher-order statistical procedures, and constituted a methodology that was robust with respect to deviations from the assumptions. There is consequently no need for the reader to be concerned about checking whether or not the required assumptions were satisfied, and because the statistical procedure was a fundamental procedure, it is easy to understand and ensures a high degree of analytical transparency. We therefore think that it is an approach that is not inferior to higher-order statistical procedures.

4\) no consideration was given to the possibility that multiple mediator factors may explain the association between exposure to anti-dementia drugs and adverse events.

4a) Taking 9-10 concurrent drugs with anti-dementia drugs was one significant risk factor of adverse events. How can it be excluded that the adverse events were caused by one of the 9-10 concurrent drugs or (even more plausible) by the pharmacodynamics/pharmacokinetics of these associations?

Response:

As you have pointed out, it is not clear what drugs or drug interactions caused the adverse events. One of the important findings of our study is that the probability of adverse events occurring increases as the number of concomitant medications increases. In general, polypharmacy is common in dementia patients, and our findings are significant from the standpoint of ensuring the safety of drug treatment. The objective of this study was to investigate risk factors, with the emphasis not on "pharmacological factors, such as drug interactions and pharmacokinetics," but rather "sociopharmaceutical factors, such as the characteristics and treatment adherence of individual patients."

4b) What does it mean \"inappropriate use\" of anti-dementia drugs? How can pharmacists have all the information to judge upon the appropriateness of anti-dementia agents\' prescription? Were the anti-dementia agents prescribed by primary-care physicians or by dementia specialists?

Response:

The questionnaire defined "inappropriate anti-dementia drug use" as cases in which either "the physician continued to prescribe an anti-dementia drug even though the patient had severe dementia for which the anti-dementia drug was not indicated" or "the physician continued to prescribe an anti-dementia drug despite the fact that the therapeutic efficacy was not being regularly assessed and clear efficacy was not being achieved."

The pharmacists responded to the survey questions based on these definitions. In Japan, pharmacist home visitation services sometimes include cases where both the physician and the pharmacist visit the patient together. In general, pharmacists who provide home visitation services acquire a better understanding of their patients' clinical conditions than pharmacists who remain at the pharmacy.

Anti-dementia drugs are prescribed by primary care physicians. Pharmacist home visitation services are mostly provided pursuant to the instructions of primary care physicians. In Japan, physicians specializing in dementia work full-time at their offices, and do not make home visits.

As noted by Reviewer \#2, there may be some limitations to this study regarding the accuracy of the pharmacists' assessments of adverse events and inappropriate use. We have therefore revised the description of the study's limitations in the "Discussion" section.
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